BALAXI — Balaxi Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Balaxi Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	456	2,313	2,794	3,364	2,413
Cost of Revenue
Gross Profit	121	592	838	1,337	1,126
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	396	1,892	2,297	2,816	2,350
Operating Profit	60.6	421	497	548	63.4
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	88.7	443	545	569	20.2
Provision for Income Taxes
Net Income After Taxes	61	381	477	460	-23.9
Net Income Before Extraordinary Items
Net Income	61	381	477	460	-23.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	61	381	477	460	-23.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.22	7.63	9.53	9.08	4.37
Dividends per Share